Developer docs
API playgroundTry for free, no card

Search company profiles

Profluent Bio

Full company profile

uuid000084e

Namestring
Profluent Bio
Legal namestring
Profluent Bio Inc.
Websiteurl
profluent.bio
Company typeenum
Private
Founded yearint
2022
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersEmeryville, United States
HQ citystring
Emeryville
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI protein design, generative protein models, gene editing systems, protein language models, AI-designed therapeutics
Industry2 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
AI Protein Design Platform
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model5 records
1Strategic R&D collaborations with milestone payments
TypeLicensing Royalties
Description

Multi-program strategic research collaborations with large pharma and biotech, generating upfront payments, research funding, and development/commercial milestone payments (e.g., Eli Lilly agreement worth up to $2.25B plus tiered royalties on net sales).

businesswire.com
2Asset licensing (molecules)
TypeLicensing Royalties
Description

Licensing of pre-designed protein assets (e.g., OpenAntibodies) for ready-made solutions to common challenges, including royalty-free or upfront-free licensing for selected antibody designs.

profluent.bio
3Foundation model API early access (ProGen3)
TypeSubscription Recurring
Description

Early access program for ProGen3 foundation models via API, enabling select partners to customize models to specific data and use cases.

profluent.bio
4Discovery partnerships / bespoke co-development
TypeProfessional Services
Description

Custom discovery engagements where Profluent's AI models and wet lab are applied to specific partner challenges (protein design, antibodies, enzymes, peptides) with relevant wet-lab validation.

profluent.bio
5Open-source licensing with commercial-use license fees
TypeOne Time License
Description

Free open-source release of OpenCRISPR-1 for ethical research and commercial use under a simple license agreement with attribution and ethical-use terms; 'no royalties' standard licensing for the open-source product line.

profluent.bio
Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 4 records shown
1OpenCRISPR
Description

The world's first AI-designed and open-source gene editor, led by the release of OpenCRISPR-1, a Cas9-like protein generated by Profluent's large language models for research and commercial use under license.

profluent.bio
+3 more records
Core offering1 text field

Profluent Bio builds frontier large language models (ProGen3 family, up to 46B parameters) trained on a proprietary 3.4B-sequence protein atlas to author novel proteins from scratch. Its integrated AI + in-house wet lab delivers AI-designed gene editors (OpenCRISPR-1), antibodies (OpenAntibodies), enzymes, and recombinases to pharmaceutical, biotechnology, and agriculture partners through discovery partnerships, asset licensing, and an early-access API program.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 8 values shown
  • 95% reduction in off-target editing vs SpCas9 while maintaining comparable on-target editing efficiency (55.7% vs 48.3% SpCas9)
+7 more records
Product overview1 text field

Profluent Bio offers an integrated AI protein design platform — a single underlying architecture combining frontier foundation models with an in-house wet-lab validation loop — that exposes its capabilities through multiple modalities. The core platform is powered by the ProGen3 foundation model suite (a family of generative protein language models trained on over 3.4 billion sequences), and from it Profluent has spun out distinct modality products: OpenCRISPR (gene editing, with the open-source OpenCRISPR-1 flagship editor), OpenAntibodies (single-shot antibody design across 20 therapeutic targets), proseLM (structure-conditioned design), and Protein2PAM (Cas-protein PAM prediction and engineering). Together these products target therapeutics, agriculture, and industrial biomanufacturing markets, accessible to partners via molecule licensing, asset licensing, or API early access.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-04-28
Description

Multi-program strategic research collaboration to develop and commercialize AI-designed site-specific recombinases for genetic medicine. Profluent will use its AI models to design custom recombinases enabling kilobase-scale DNA editing, while Lilly receives exclusive rights to advance candidates through research, development, and commercialization. Profluent is eligible to receive up to $2.25 billion in development and commercial milestone payments plus tiered royalties on net sales.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-12-09
Description

Strategic collaboration to develop AI-designed base editors for in vivo hematopoietic stem cell therapies. The companies aim to leverage AI technology to create advanced gene editing tools that could improve treatments for hematologic and immune diseases.

Strategic tierMinorTypeOthersAnnounced on2025-11-24
Description

Legal advisor to Profluent Bio on its $106M financing round for AI-driven protein design.

Strategic tierSignificantTypeStrategic or Co-development PartnerAnnounced on2025-11-17
Description

Partnership to design AI-based gene editing therapies for Rett syndrome, with RSRT awarding Profluent $1M in initial funding. Profluent will leverage its AI models to develop base editors that correct mutations in the MECP2 gene, starting with the T158M mutation, with the goal of creating custom editing solutions delivered via adeno-associated virus.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-10-21
Description

Collaboration to develop new enzymes using AI-driven protein design and genomics expertise, combining Profluent's generative AI platform with IDT's enzyme engineering and genomics expertise. Aims to accelerate development of enzymes for applications including epigenetics, cancer research, sequencing, and gene editing.

6Corteva Agriscience
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-10-06
Description

Multi-year strategic collaboration to use generative AI for developing sustainable and resilient crops. The partnership involves designing gene editing systems and testing them in agricultural applications, aiming to accelerate crop development.

trendhunter.com
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-09-22
Description

Collaboration to launch AI-enhanced adenine deaminase pin-point base editing systems. Revvity partnership incorporates AI-designed enzymes into base editors for cell and gene therapy applications.

8Fraser Kelton
Strategic tierMinorTypeOthersAnnounced on2023-01-01
Description

Profluent advisor and investor; former Head of Product for ChatGPT & DALL-E at OpenAI. Quote: 'Just as ChatGPT can write compelling essays and emails, Profluent has developed AI that designs entirely new and functional proteins.'

profluent.bio
9James Fraser
Strategic tierMinorTypeOthersAnnounced on2023-01-01
Description

Profluent advisor; Professor and Chair, Department of Bioengineering and Therapeutic Sciences, UCSF. Co-author of the Profluent Nature Biotechnology paper validating AI-designed proteins.

profluent.bio
10Richard Socher
Strategic tierMinorTypeOthersAnnounced on2023-01-01
Description

Profluent advisor and former Chief Scientist at Salesforce, Stanford Professor, CEO of You.com. Co-author of the Profluent Nature Biotechnology paper. Quote: 'The next frontier modality of large language models will be in proteins and biology.'

profluent.bio
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Flagship generative biology company using foundation models to design novel protein therapeutics across multiple modalities. Directly comparable to Profluent in using AI to author de novo proteins and partnering with large pharma (e.g., Amgen, Novartis).

2Isomorphic Labs
TypeDirect peer
Description

Alphabet/DeepMind spinout building frontier AI for drug discovery and protein structure/design, with major pharma partnerships (Eli Lilly, Novartis). Closest large-capital analog applying foundation models to protein engineering and pharma collaborations.

TypeDirect peer
Description

AI research lab building frontier protein language models (ESM3) for generative protein design. Directly competes on the foundation-model layer for protein generation that underpins Profluent's ProGen3 platform.

TypeDirect peer
Description

Machine-learning-driven drug discovery company combining AI with high-throughput biology. Comparable in pairing frontier ML with an in-house wet lab and pursuing pharma partnerships to translate models into therapeutics.

TypeDirect peer
Description

AI protein design platform for engineering enzymes, binders, and other proteins, with a self-serve/partner model and pharma customers. Direct competitor in generative protein engineering with similar discovery-as-a-service commercial motion.

TypeDirect peer
Description

Generative AI company designing de novo antibodies and other biologics with a zero-shot drug creation platform. Comparable in applying foundation models to antibody design and pursuing pharma co-development deals.

TypeBroad incumbent
Description

Established AI-enabled antibody discovery platform with large pharma partnerships. Broader incumbent that overlaps with Profluent's OpenAntibodies modality on therapeutic antibody discovery but at much greater scale and with conventional screening-first methods.

TypeBroad incumbent
Description

Large synthetic biology platform combining automated wet labs with AI/ML for cell engineering and protein design. Overlaps with Profluent on enzyme and protein engineering partnerships, particularly given Profluent's GM Biologics previously led BD at Ginkgo.

TypeBroad incumbent
Description

Gene writing company developing novel DNA-rewriting technologies for genetic medicine. Comparable strategic positioning with Profluent on AI-designed recombinases and programmable gene editing therapeutics.

TypeBroad incumbent
Description

Clinical-stage base editing company developing precision genetic medicines. Comparable to Profluent on base editing modality, where Profluent's ProseLM-designed base editors (~50% efficiency gains) directly compete with Beam's editing platform.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
Yes

Docs URL, Description

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Profluent Bio

AI Protein Design Platformprofluent.bio

Profluent Bio firmographics

Firmographics
Name
Profluent Bio
Legal name
Profluent Bio Inc.
Website
https://profluent.bio
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
51–100 employees
Ownership category
akta.pro rank

Profluent Bio industry classification

Industry
Product category
AI Protein Design Platform
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • AI protein design
  • Generative protein models
  • Gene editing systems
  • Protein language models
  • AI-designed therapeutics

Where Profluent Bio is headquartered

Location

Headquarters

HQ city
Emeryville
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Profluent Bio business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Strategic R&D collaborations with milestone payments: Multi-program strategic research collaborations with large pharma and biotech, generating upfront payments, research funding, and development/commercial milestone payments (e.g., Eli Lilly agreement worth up to $2.25B plus tiered royalties on net sales).
  2. Asset licensing (molecules): Licensing of pre-designed protein assets (e.g., OpenAntibodies) for ready-made solutions to common challenges, including royalty-free or upfront-free licensing for selected antibody designs.
  3. Foundation model API early access (ProGen3): Early access program for ProGen3 foundation models via API, enabling select partners to customize models to specific data and use cases.
  4. Discovery partnerships / bespoke co-development: Custom discovery engagements where Profluent's AI models and wet lab are applied to specific partner challenges (protein design, antibodies, enzymes, peptides) with relevant wet-lab validation.
  5. Open-source licensing with commercial-use license fees: Free open-source release of OpenCRISPR-1 for ethical research and commercial use under a simple license agreement with attribution and ethical-use terms; 'no royalties' standard licensing for the open-source product line.

Go-to-market motion1 record

Distribution channels5 records

Profluent Bio product offering

Product offering

Core offering

Profluent Bio builds frontier large language models (ProGen3 family, up to 46B parameters) trained on a proprietary 3.4B-sequence protein atlas to author novel proteins from scratch. Its integrated AI + in-house wet lab delivers AI-designed gene editors (OpenCRISPR-1), antibodies (OpenAntibodies), enzymes, and recombinases to pharmaceutical, biotechnology, and agriculture partners through discovery partnerships, asset licensing, and an early-access API program.

Product overview

Profluent Bio offers an integrated AI protein design platform — a single underlying architecture combining frontier foundation models with an in-house wet-lab validation loop — that exposes its capabilities through multiple modalities. The core platform is powered by the ProGen3 foundation model suite (a family of generative protein language models trained on over 3.4 billion sequences), and from it Profluent has spun out distinct modality products: OpenCRISPR (gene editing, with the open-source OpenCRISPR-1 flagship editor), OpenAntibodies (single-shot antibody design across 20 therapeutic targets), proseLM (structure-conditioned design), and Protein2PAM (Cas-protein PAM prediction and engineering). Together these products target therapeutics, agriculture, and industrial biomanufacturing markets, accessible to partners via molecule licensing, asset licensing, or API early access.

Differentiator

Problem solved

Functional benefit

Brands

  • OpenCRISPR: The world's first AI-designed and open-source gene editor, led by the release of OpenCRISPR-1, a Cas9-like protein generated by Profluent's large language models for research and commercial use under license.
  • ProGen3
  • OpenAntibodies
  • Protein2PAM

Quantifiable outcome

  • 95% reduction in off-target editing vs SpCas9 while maintaining comparable on-target editing efficiency (55.7% vs 48.3% SpCas9)
  • +7 more outcomes

Companies that use Profluent Bio

Customer profile

Named customers1 record

Ideal customer profiles5 records

Profluent Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
Yes
API docs
API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature6 records

Profluent Bio partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered flagship, major, minor and significant.

  • Eli LillyflagshipStrategic or Co-development Partner · 28 April 2026Multi-program strategic research collaboration to develop and commercialize AI-designed site-specific recombinases for genetic medicine. Profluent will use its AI models to design custom recombinases enabling kilobase-scale DNA editing, while Lilly receives exclusive rights to advance candidates through research, development, and commercialization. Profluent is eligible to receive up to $2.25 billion in development and commercial milestone payments plus tiered royalties on net sales.
  • EnsomamajorStrategic or Co-development Partner · 9 December 2025Strategic collaboration to develop AI-designed base editors for in vivo hematopoietic stem cell therapies. The companies aim to leverage AI technology to create advanced gene editing tools that could improve treatments for hematologic and immune diseases.
  • Ropes & GrayminorOthers · 24 November 2025Legal advisor to Profluent Bio on its $106M financing round for AI-driven protein design.
  • Rett Syndrome Research Trust (RSRT)significantStrategic or Co-development Partner · 17 November 2025Partnership to design AI-based gene editing therapies for Rett syndrome, with RSRT awarding Profluent $1M in initial funding. Profluent will leverage its AI models to develop base editors that correct mutations in the MECP2 gene, starting with the T158M mutation, with the goal of creating custom editing solutions delivered via adeno-associated virus.
  • Integrated DNA Technologies (IDT, a Danaher company)majorStrategic or Co-development Partner · 21 October 2025Collaboration to develop new enzymes using AI-driven protein design and genomics expertise, combining Profluent's generative AI platform with IDT's enzyme engineering and genomics expertise. Aims to accelerate development of enzymes for applications including epigenetics, cancer research, sequencing, and gene editing.
  • Corteva AgrisciencemajorStrategic or Co-development Partner · 6 October 2025Multi-year strategic collaboration to use generative AI for developing sustainable and resilient crops. The partnership involves designing gene editing systems and testing them in agricultural applications, aiming to accelerate crop development.
  • RevvitymajorStrategic or Co-development Partner · 22 September 2025Collaboration to launch AI-enhanced adenine deaminase pin-point base editing systems. Revvity partnership incorporates AI-designed enzymes into base editors for cell and gene therapy applications.
  • Fraser KeltonminorOthers · 1 January 2023Profluent advisor and investor; former Head of Product for ChatGPT & DALL-E at OpenAI. Quote: 'Just as ChatGPT can write compelling essays and emails, Profluent has developed AI that designs entirely new and functional proteins.'
  • James FraserminorOthers · 1 January 2023Profluent advisor; Professor and Chair, Department of Bioengineering and Therapeutic Sciences, UCSF. Co-author of the Profluent Nature Biotechnology paper validating AI-designed proteins.
  • Richard SocherminorOthers · 1 January 2023Profluent advisor and former Chief Scientist at Salesforce, Stanford Professor, CEO of You.com. Co-author of the Profluent Nature Biotechnology paper. Quote: 'The next frontier modality of large language models will be in proteins and biology.'

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Profluent Bio competitors and assessment

Company assessment

Direct peers

  • Generate Biomedicines: Flagship generative biology company using foundation models to design novel protein therapeutics across multiple modalities. Directly comparable to Profluent in using AI to author de novo proteins and partnering with large pharma (e.g., Amgen, Novartis).
  • Isomorphic Labs: Alphabet/DeepMind spinout building frontier AI for drug discovery and protein structure/design, with major pharma partnerships (Eli Lilly, Novartis). Closest large-capital analog applying foundation models to protein engineering and pharma collaborations.
  • EvolutionaryScale: AI research lab building frontier protein language models (ESM3) for generative protein design. Directly competes on the foundation-model layer for protein generation that underpins Profluent's ProGen3 platform.
  • Insitro: Machine-learning-driven drug discovery company combining AI with high-throughput biology. Comparable in pairing frontier ML with an in-house wet lab and pursuing pharma partnerships to translate models into therapeutics.
  • Cradle Bio: AI protein design platform for engineering enzymes, binders, and other proteins, with a self-serve/partner model and pharma customers. Direct competitor in generative protein engineering with similar discovery-as-a-service commercial motion.
  • Absci: Generative AI company designing de novo antibodies and other biologics with a zero-shot drug creation platform. Comparable in applying foundation models to antibody design and pursuing pharma co-development deals.

Broad incumbents

  • AbCellera Biologics: Established AI-enabled antibody discovery platform with large pharma partnerships. Broader incumbent that overlaps with Profluent's OpenAntibodies modality on therapeutic antibody discovery but at much greater scale and with conventional screening-first methods.
  • Ginkgo Bioworks: Large synthetic biology platform combining automated wet labs with AI/ML for cell engineering and protein design. Overlaps with Profluent on enzyme and protein engineering partnerships, particularly given Profluent's GM Biologics previously led BD at Ginkgo.
  • Tessera Therapeutics: Gene writing company developing novel DNA-rewriting technologies for genetic medicine. Comparable strategic positioning with Profluent on AI-designed recombinases and programmable gene editing therapeutics.
  • Beam Therapeutics: Clinical-stage base editing company developing precision genetic medicines. Comparable to Profluent on base editing modality, where Profluent's ProseLM-designed base editors (~50% efficiency gains) directly compete with Beam's editing platform.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Profluent Bio social profiles

Digital presence

Profluent Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Profluent Bio leadership team

Management profile

Number of profiles

Profiles11 records

Profluent Bio funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Profluent Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Profluent Bio

What does Profluent Bio do?

Profluent Bio builds frontier large language models (ProGen3 family, up to 46B parameters) trained on a proprietary 3.4B-sequence protein atlas to author novel proteins from scratch. Its integrated AI + in-house wet lab delivers AI-designed gene editors (OpenCRISPR-1), antibodies (OpenAntibodies), enzymes, and recombinases to pharmaceutical, biotechnology, and agriculture partners through discovery partnerships, asset licensing, and an early-access API program.

Is Profluent Bio a public or private company?

Profluent Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was Profluent Bio founded?

Profluent Bio was founded in 2022. It employs 51 to 100 people.

Where is Profluent Bio based?

Profluent Bio is headquartered in Emeryville, United States, in the North America region.

How does Profluent Bio make money?

Five revenue lines are on record. Strategic R&D collaborations with milestone payments are the primary driver. The others are asset licensing (molecules), foundation model API early access (ProGen3), discovery partnerships / bespoke co-development and open-source licensing with commercial-use license fees.

Who are Profluent Bio's main competitors?

Direct peers on record are Generate Biomedicines, Isomorphic Labs, EvolutionaryScale, Insitro, Cradle Bio and Absci. Broad incumbents are AbCellera Biologics, Ginkgo Bioworks, Tessera Therapeutics and Beam Therapeutics.

Does Profluent Bio have an API?

Yes. Profluent offers a partner-facing API providing early access to its foundation protein generation models. Partners can sign up for an early access program to customize Profluent's best foundation models to specific data or use-cases. Access is currently gated via a sign-up form. An SDK language is not specified. Developer documentation is at docs.google.com/forms/d/1PdkbQcPdS_mXx4O_GS-7o2tFcYwaLzOvW138IPiIrtQ.

What industry is Profluent Bio in?

Profluent Bio's product category is AI Protein Design Platform. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogProfluent Named 2026 Emerging Innovator Of The Year At 23rd Annual Pantheon AwardsProfluent was named Emerging Innovator of the Year at the 23rd Annual Pantheon Awards on November 12, 2026, in San Francisco. The award recognizes its AI design platform, with judges citing experimental validation and industry partnerships. The company, founded in 2022, is backed by investors including Altimeter Capital and Bezos Expeditions.FinancialContent Business PageProfluent Named 2026 Emerging Innovator Of The Year At 23rd Annual Pantheon AwardsProfluent was named Emerging Innovator of the Year at the 23rd Annual Pantheon Awards on November 12, 2026, in San Francisco. The award recognizes its AI design platform and original approach to AI in life sciences, with judges citing experimental validation and industry partnerships.Pharmaceutical TechnologyBioMarin, Profluent partner on AI-designed enzyme therapiesBioMarin Pharmaceutical entered a research collaboration with Profluent to design and optimize novel enzyme therapies using Profluent's protein language models. Profluent will use its Protein Atlas dataset of over 115 billion sequences, while BioMarin screens outputs for target activity and stability. The partnership aims to accelerate drug discovery for unmet needs.MarketScreenerProfluent And BioMarin Pharmaceutical Inc. Partner To Design Novel Medicines Using AIProfluent and BioMarin Pharmaceutical announced a collaboration to design and optimize novel enzyme therapies for BioMarin's pipeline. Profluent will apply its AI models to generate potential drug candidates, while BioMarin will screen results to advance promising designs into preclinical testing.Business Wire BlogProfluent Partners With BioMarin to Design Novel Medicines Using AIProfluent and BioMarin announced a collaboration to design and optimize novel enzyme therapies for BioMarin's pipeline. Profluent will use its proprietary protein language models, trained on over 115 billion sequences, to generate candidates, while BioMarin will screen and advance the most promising designs.BioSpaceGEMMABio Awarded ARPA-H Funding to Pursue Innovative Base-editing Strategy for Rare Liver DiseasesGEMMABio received ARPA-H funding to develop AI-designed base-editing products for rare liver diseases, partnering with Profluent Bio. The project targets four founder mutations in homozygous familial hypercholesterolemia and maple syrup urine disease using lipid nanoparticle delivery. The collaboration aims to establish a proof-of-concept for scalable, low-cost personalized gene editing.BostonGlobe.comARPA-H launches $160 million effort to develop custom gene editing drugsARPA-H, the US health research "moonshot" agency, announced Thursday it will spend up to $160 million on a program called THRIVE to develop custom gene editing treatments for rare diseases. The program will back seven different teams pursuing treatments for conditions affecting different organ systems, including metabolic disorders, immune disorders, blood disorders, pediatric epilepsies, genetic heart disease, blood vessel diseases, and skin diseases. The funded institutions include Children's Hospital of Philadelphia, UC Berkeley with the Innovative Genomics Institute, St. Jude Children's Research Hospital, Broad Institute, GemmaBio with Profluent Bio, Massachusetts General Hospital, and Stanford University.Labiotech.euTop biotech deals in April 2026April 2026 witnessed major biotech M&A activity with the largest deal being Sun Pharma's $11.75 billion acquisition of New Jersey-based Organon, giving the Indian pharma access to over 140 markets including China and Brazil. American giant Lilly made four deals in the month totaling over $11 billion, including acquisitions of Kelonia Therapeutics ($7B), Ajax Therapeutics ($2.3B), CrossBridge Bio (up to $300M), and a partnership with AI-protein design firm Profluent (up to $2.25B). The broader April deal flow included transactions across antibody-drug conjugates, AI platforms, T-cell engagers, and rare disease therapeutics, with companies like Gilead, Roche, Bristol Myers Squibb, and AbbVie also participating in significant partnerships.BioSpaceLilly can’t stop the dealing, with nearly $21B spent on M&A this year—so farEli Lilly has spent nearly $21 billion on six acquisitions in 2025 alone, already exceeding its single-year deal total from the past decade, as executives reinvest GLP-1 obesity revenue into pipeline expansion. Key deals include partnerships with Profluent Bio (up to $2.25 billion for AI-driven DNA editing tools) and Ajax Therapeutics (up to $2.3 billion for rare blood cancer treatments), along with the $300 million acquisition of CrossBridge Bio to bolster its cancer portfolio. Analysts at Leerink Partners noted the deal activity demonstrates aggressive reinvestment of obesity cash flows, with Lilly reporting over $65 billion in 2025 revenue and $7.3 billion in cash available to fund additional transactions.Pharmaceutical TechnologyEli Lilly bets on recombinases in $2.25bn Profluent R&D pact - Pharmaceutical TechnologyEli Lilly partnered with AI biotech Profluent to develop recombinases for large-scale gene editing, with Lilly paying an undisclosed upfront and funding R&D. The deal could earn Profluent up to $2.25bn in milestones and tiered royalties, and Lilly gained exclusive rights to selected recombinases.